Drug intelligence / Profile preview

MVA-mBN120B

Development stage: Phase 1
Lead developer: Bavarian Nordic
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

MVA-mBN120B is a recombinant Modified Vaccinia Ankara (MVA) based viral vector vaccine developed by Bavarian Nordic for the treatment of HIV infection. It is designed as a multiantigen vaccine, expressing several HIV-1 antigens to elicit a broad T-cell immune response. The vaccine utilizes the MVA-BN platform, which is a highly attenuated, non-replicating orthopoxvirus vector. In clinical trials, it has been evaluated for safety and immunogenicity in HIV-infected individuals with preserved CD4 counts, administered via subcutaneous injection.

Other names: MVA-BN HIV Multiantigen

Targets

HIV (HIV-1 enzymes)

Beyond the preview

Go deeper on MVA-mBN120B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVA-mBN120B.

Explore the full profile